Innovative Contracting Models: Redefining Market Access Strategies for Specialty and Rare Disease Drugs

This report delves into the strategic use of innovative contracting within the pharmaceutical industry, offering a comprehensive analysis of when and how these contracts can be effectively utilised to secure market access. It provides insights into the current landscape of innovative contracting, highlighting the conditions under which these agreements are most viable and beneficial.

Gain an understanding of the challenges and opportunities associated with innovative contracts, including their application in high-cost treatments like oncology and gene therapies. The report also explores the role of predictive analytics and AI in shaping contracting strategies and addresses the practical considerations necessary for successful implementation. With contributions from industry experts, this report equips pharmaceutical professionals with the knowledge to navigate the complexities of innovative contracting and optimise their market access strategies.

Key Questions Answered:

• 1. What are the significant developments and market trends in innovative contracting?
• 2. How can companies identify when an innovative contract is a viable market access option?
• 3. What criteria qualify experts to provide insights on innovative contracting?
• 4. How do different markets, including Europe and the US, approach innovative contracting?
• 5. What are the challenges and opportunities associated with innovative contracting?
• 6. How can companies optimise their market access strategies using innovative contracts?

Key Companies:

Partial List of Participating Experts:

• Vice President, Innovative Contracting, Verpora, based in the UK but covering the globe
• Vice President, Real World Evidence, Prescient, based in the UK but covering the globe
• Market Access, at a top 30 pharmaceutical company by 2023 global sales, based in the US

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.